vs
ADMA BIOLOGICS, INC.（ADMA）与STURM RUGER & CO INC（RGR）财务数据对比。点击上方公司名可切换其他公司
STURM RUGER & CO INC的季度营收约是ADMA BIOLOGICS, INC.的1.1倍（$151.1M vs $139.2M），ADMA BIOLOGICS, INC.同比增速更快（18.4% vs 3.6%），ADMA BIOLOGICS, INC.自由现金流更多（$34.6M vs $12.3M），过去两年ADMA BIOLOGICS, INC.的营收复合增速更高（30.4% vs 5.1%）
ADMA生物制剂公司是一家专注于研发、生产及商业化特种血浆来源免疫球蛋白疗法的生物制药企业，主要面向美国市场，为原发性免疫缺陷及其他免疫相关疾病患者、医护人员和医疗机构提供免疫健康领域的治疗方案。
鲁格公司（Ruger）是总部位于美国康涅狄格州绍斯波特的枪械制造企业，除总部外，还在新罕布什尔州纽波特、北卡罗来纳州梅约丹以及亚利桑那州普雷斯科特设有生产工厂。公司由亚历山大·麦考密克·斯特姆与威廉·B·鲁格于1949年共同创立，自1969年起公开上市交易。
ADMA vs RGR — 直观对比
营收规模更大
RGR
是对方的1.1倍
$139.2M
营收增速更快
ADMA
高出14.8%
3.6%
自由现金流更多
ADMA
多$22.2M
$12.3M
两年增速更快
ADMA
近两年复合增速
5.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $139.2M | $151.1M |
| 净利润 | $49.4M | — |
| 毛利率 | 63.8% | 17.8% |
| 营业利润率 | 45.1% | 2.3% |
| 净利率 | 35.5% | — |
| 营收同比 | 18.4% | 3.6% |
| 净利润同比 | -55.9% | — |
| 每股收益（稀释后） | $0.20 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADMARGR
| Q4 25 | $139.2M | $151.1M | ||
| Q3 25 | $134.2M | $126.8M | ||
| Q2 25 | $122.0M | $132.5M | ||
| Q1 25 | $114.8M | $135.7M | ||
| Q4 24 | $117.5M | $145.8M | ||
| Q3 24 | $119.8M | $122.3M | ||
| Q2 24 | $107.2M | $130.8M | ||
| Q1 24 | $81.9M | $136.8M |
净利润ADMARGR
| Q4 25 | $49.4M | — | ||
| Q3 25 | $36.4M | $1.6M | ||
| Q2 25 | $34.2M | $-17.2M | ||
| Q1 25 | $26.9M | $7.8M | ||
| Q4 24 | $111.9M | — | ||
| Q3 24 | $35.9M | $4.7M | ||
| Q2 24 | $32.1M | $8.3M | ||
| Q1 24 | $17.8M | $7.1M |
毛利率ADMARGR
| Q4 25 | 63.8% | 17.8% | ||
| Q3 25 | 56.3% | 15.1% | ||
| Q2 25 | 55.1% | 3.9% | ||
| Q1 25 | 53.2% | 22.0% | ||
| Q4 24 | 53.9% | 22.8% | ||
| Q3 24 | 49.8% | 18.5% | ||
| Q2 24 | 53.6% | 22.3% | ||
| Q1 24 | 47.8% | 21.5% |
营业利润率ADMARGR
| Q4 25 | 45.1% | 2.3% | ||
| Q3 25 | 38.0% | -2.7% | ||
| Q2 25 | 35.1% | -15.6% | ||
| Q1 25 | 30.4% | 6.2% | ||
| Q4 24 | 32.6% | 7.8% | ||
| Q3 24 | 33.1% | 3.1% | ||
| Q2 24 | 36.6% | 6.9% | ||
| Q1 24 | 26.7% | 5.5% |
净利率ADMARGR
| Q4 25 | 35.5% | — | ||
| Q3 25 | 27.1% | 1.2% | ||
| Q2 25 | 28.1% | -13.0% | ||
| Q1 25 | 23.4% | 5.7% | ||
| Q4 24 | 95.2% | — | ||
| Q3 24 | 30.0% | 3.9% | ||
| Q2 24 | 29.9% | 6.3% | ||
| Q1 24 | 21.7% | 5.2% |
每股收益（稀释后）ADMARGR
| Q4 25 | $0.20 | $0.22 | ||
| Q3 25 | $0.15 | $0.10 | ||
| Q2 25 | $0.14 | $-1.05 | ||
| Q1 25 | $0.11 | $0.46 | ||
| Q4 24 | $0.45 | $0.62 | ||
| Q3 24 | $0.15 | $0.28 | ||
| Q2 24 | $0.13 | $0.47 | ||
| Q1 24 | $0.08 | $0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $87.6M | $92.5M |
| 总债务越低越好 | $72.1M | — |
| 股东权益账面价值 | $477.3M | $283.8M |
| 总资产 | $624.2M | $342.0M |
| 负债/权益比越低杠杆越低 | 0.15× | — |
8季度趋势，按日历期对齐
现金及短期投资ADMARGR
| Q4 25 | $87.6M | $92.5M | ||
| Q3 25 | $61.4M | $80.8M | ||
| Q2 25 | $90.3M | $101.4M | ||
| Q1 25 | $71.6M | $108.3M | ||
| Q4 24 | $103.1M | $105.5M | ||
| Q3 24 | $86.7M | $96.0M | ||
| Q2 24 | $88.2M | $105.6M | ||
| Q1 24 | $45.3M | $115.3M |
总债务ADMARGR
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ADMARGR
| Q4 25 | $477.3M | $283.8M | ||
| Q3 25 | $431.2M | $279.6M | ||
| Q2 25 | $398.3M | $289.3M | ||
| Q1 25 | $373.4M | $321.5M | ||
| Q4 24 | $349.0M | $319.6M | ||
| Q3 24 | $231.9M | $314.9M | ||
| Q2 24 | $188.3M | $321.5M | ||
| Q1 24 | $153.7M | $332.0M |
总资产ADMARGR
| Q4 25 | $624.2M | $342.0M | ||
| Q3 25 | $568.7M | $342.3M | ||
| Q2 25 | $558.4M | $349.5M | ||
| Q1 25 | $510.6M | $379.0M | ||
| Q4 24 | $488.7M | $384.0M | ||
| Q3 24 | $390.6M | $373.5M | ||
| Q2 24 | $376.4M | $376.7M | ||
| Q1 24 | $350.9M | $385.0M |
负债/权益比ADMARGR
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $35.6M | $15.5M |
| 自由现金流经营现金流 - 资本支出 | $34.6M | $12.3M |
| 自由现金流率自由现金流/营收 | 24.8% | 8.2% |
| 资本支出强度资本支出/营收 | 0.8% | 2.1% |
| 现金转化率经营现金流/净利润 | 0.72× | — |
| 过去12个月自由现金流最近4个季度 | $27.8M | $38.5M |
8季度趋势，按日历期对齐
经营现金流ADMARGR
| Q4 25 | $35.6M | $15.5M | ||
| Q3 25 | $13.3M | $12.9M | ||
| Q2 25 | $21.1M | $14.7M | ||
| Q1 25 | $-19.7M | $11.1M | ||
| Q4 24 | $50.2M | $20.0M | ||
| Q3 24 | $25.0M | $9.4M | ||
| Q2 24 | $45.6M | $18.7M | ||
| Q1 24 | $-2.2M | $7.3M |
自由现金流ADMARGR
| Q4 25 | $34.6M | $12.3M | ||
| Q3 25 | $-1.1M | $7.0M | ||
| Q2 25 | $18.7M | $9.1M | ||
| Q1 25 | $-24.4M | $10.0M | ||
| Q4 24 | $47.5M | $16.4M | ||
| Q3 24 | $24.0M | $2.6M | ||
| Q2 24 | $43.6M | $10.1M | ||
| Q1 24 | $-4.6M | $5.6M |
自由现金流率ADMARGR
| Q4 25 | 24.8% | 8.2% | ||
| Q3 25 | -0.8% | 5.5% | ||
| Q2 25 | 15.3% | 6.9% | ||
| Q1 25 | -21.2% | 7.4% | ||
| Q4 24 | 40.4% | 11.2% | ||
| Q3 24 | 20.0% | 2.1% | ||
| Q2 24 | 40.7% | 7.7% | ||
| Q1 24 | -5.6% | 4.1% |
资本支出强度ADMARGR
| Q4 25 | 0.8% | 2.1% | ||
| Q3 25 | 10.7% | 4.6% | ||
| Q2 25 | 2.0% | 4.2% | ||
| Q1 25 | 4.1% | 0.8% | ||
| Q4 24 | 2.3% | 2.5% | ||
| Q3 24 | 0.9% | 5.5% | ||
| Q2 24 | 1.9% | 6.6% | ||
| Q1 24 | 2.9% | 1.3% |
现金转化率ADMARGR
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | 8.15× | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | -0.73× | 1.43× | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | 1.98× | ||
| Q2 24 | 1.42× | 2.27× | ||
| Q1 24 | -0.12× | 1.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
